mTOR inhibitor for the treatment of hepatocellular carcinoma (Q37914634)

25 August 2017

1 reference

title

mTOR inhibitor for the treatment of hepatocellular carcinoma (English)

1 reference

25 August 2017

Masatoshi Kudo

1

0 references

publication date

9 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

29

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

310-315

1 reference

TOR signaling in growth and metabolism

25 August 2017

cites work

1 reference

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

TOR, a central controller of cell growth

21 January 2018

1 reference

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

Hypoxia signalling in cancer and approaches to enforce tumour regression

21 January 2018

1 reference

Eukaryotic Translation Initiation Factor 4E Regulates Expression of Cyclin D1 at Transcriptional and Post-transcriptional Levels

21 January 2018

1 reference

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

21 January 2018

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).

21 January 2018

1 reference

Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer

21 January 2018

1 reference

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

21 January 2018

1 reference

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

21 January 2018

1 reference

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

21 January 2018

1 reference

Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer

21 January 2018

1 reference

mTOR and P70 S6 kinase expression in primary liver neoplasms

21 January 2018

1 reference

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

21 January 2018

1 reference

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000327565

1 reference

25 August 2017

1 reference